US FDA approves Otsuka's kidney disease drug-June 2024-www.financetom.com

US FDA approves Otsuka's kidney disease drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves Otsuka's kidney disease drug

Nov 25, 2025 12:23 PM

Nov 25 (Reuters) - The U.S. Food and Drug Administration

has approved Otsuka's injectable drug to treat patients

with a potentially life-threatening kidney disease, the health

regulator's website showed on Tuesday.

Previous page： NYCB closes $1 billion capital infusion deal Next page： US judge to hear FTC challenge to Kroger-Albertsons deal in August

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

NYCB closes $1 billion capital infusion deal

Mar 11, 2024

(Reuters) -New York Community Bancorp ( NYCB ) said on Monday it had closed the $1 billion capital infusion deal that was agreed last week with an investor group and plans to submit one-for-three reverse stock split of its common stock to shareholders. Last week, Joseph Otting, former Comptroller of the Currency in the Trump administration, was named NYCB's chief...

US judge to hear FTC challenge to Kroger-Albertsons deal in August

Mar 11, 2024

WASHINGTON (Reuters) -U.S. District Judge Adrienne Nelson on Monday set Aug. 26 as the start of a hearing on the Federal Trade Commission's bid for a preliminary injunction to block supermarket chain Kroger's $24.6 billion deal to buy smaller rival Albertsons. The FTC sued last month to block the deal that would create a supermarket empire with more than 4,000...

NYCB closes $1 billion capital infusion deal

Mar 11, 2024

March 11 (Reuters) - New York Community Bancorp ( NYCB ) said on Monday it had closed the $1 billion capital infusion deal that was agreed last week with an investor group. ...

Blackwells urges Disney shareholders to disregard ValueAct's board endorsement

Mar 11, 2024

March 11 (Reuters) - Walt Disney ( DIS ) investor Blackwells Capital said on Monday it urged shareholders to disregard ValueAct's endorsement of Walt Disney's ( DIS ) board. Blackwells said its diligence showed that the board had failed to disclose that ValueAct or its affiliates have been managing more than $350 million of Disney's ( DIS ) pension fund...